CollPlant Biotechnologies Ltd (CLGN) shareholders
Close on Nov 11, 2026Market cap $5.72MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| The Loewenbaum 1992 Trust Joint filing with George Walter Loewenbaum (6.20%) | 3,597,047 | 17.50% | 13D (active) amendment | Aug 19, 2026 |
| George Walter Loewenbaum | 1,256,056 | 9.90% | 13D (active) amendment | Nov 6, 2025 |
| Ami Sagy | 163,709 | 5.70% | 13D (active) amendment | Sep 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CLGN | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Parallel Advisors, LLC | 7 | – | $25 | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|
| Q2 2026 | 1 | 0M | 0 / 0 | 0 / 0 | 0M | 0M |
| Q1 2026 | 1 | 0M | 0 / 0 | 1 / 0 | 0M | 0M |
| Q4 2025 | 1 | 0M | 0 / 0 | 0 / 0 | 0M | 0M |
| Q3 2025 | 1 | 0M | 0 / 0 | 0 / 0 | 0M | 0M |
| Q2 2025 | 1 | 0M | 0 / 0 | 0 / 0 | 0M | 0M |
| Q1 2025 | 1 | 0M | 0 / 0 | 0 / 0 | 0M | 0M |
| Q4 2024 | 1 | 0M | 0 / 0 | 0 / 0 | 0M | 0M |
| Q3 2024 | 1 | 0M | 0 / 0 | 0 / 0 | 0M | 0M |
| Q2 2024 | 1 | 0M | 0 / 0 | 1 / 0 | 0M | 0M |
| Q1 2024 | 1 | 0M | 0 / 1 | 0 / 0 | 0M | 0M |
| Q4 2023 | 1 | 0M | 0 / 0 | 1 / 0 | 0M | 0M |
| Q3 2023 | 1 | 0M | 0 / 0 | 1 / 0 | 0M | 0M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | Latest filing |
|---|---|---|---|
| Yehiel Tal | Chief Executive Officer, Director | 31,137 | Mar 19, 2026 |
| Bar Berta Abelis | VP Legal | 206,441 | Sep 8, 2026 |
| Eran Rotem | Deputy CEO and CFO | 516,372 | Sep 8, 2026 |
| Philippe Bensimon | VP Regulations and QA | 2,000 | Mar 18, 2026 |
| Jasmine Seror | VP Product Development | 45,000 | Mar 18, 2026 |
| Bowman Bagley | VP Commercial North America | 25,000 | Mar 18, 2026 |
| Oren Fahimipoor | VP Operations | 30,000 | Mar 18, 2026 |
| Ruty Ben Shlomi | Director | 66,501 | Oct 19, 2026 |
| Hugh M. Evans | Director | 325,554 | Apr 27, 2026 |
| Elan Penn | Director | 7,500 | Mar 18, 2026 |
| Avraham Havron | Director | 10,000 | Mar 18, 2026 |
| Alisa Lask | Director | 10,000 | Mar 18, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Bar Berta Abelis VP Legal | Sep 3, 2026 | Award | +201,141 | – | – | 206,441 |
| Eran Rotem Deputy CEO and CFO | Sep 3, 2026 | Award | +510,372 | – | – | 516,372 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of CollPlant Biotechnologies's stock actually held short. Settlement fails (shares not delivered on time) peaked at 2,396,116 shares on Sep 1, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Loewenbaum Lilian S. 10% Stockholder | Oct 27, 2026 | 15,550 | $58.93K | Oct 27, 2026 | Open Market Purchase |
| Ami Sagy Shareholder | Oct 9, 2025 | 140,000 | $308.00K | Oct 10, 2025 | Private placement from Issuer |
| Ami Sagy Shareholder | Sep 22, 2023 | 56,098 | $336.59K | Sep 21, 2023 | Ami Sagy |
| Ami Sagy Shareholder | Sep 12, 2023 | 87,853 | $633.42K | Sep 12, 2023 | Ami Sagy |
| Sagy Ami 10% Stockholder | Jun 14, 2023 | 110,000 | $798.60K | Jun 14, 2023 | Private Placement |
See a number that looks wrong?